Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,424
archived clinical trials in
Cognitive Studies

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 010
mi
from
Media, PA
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 010
mi
from
Media, PA
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative site 066
mi
from
Charleston, SC
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative site 066
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 128
mi
from
Sioux Falls, SD
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 128
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site
mi
from
Memphis, TN
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 057
mi
from
Nashville, TN
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 057
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 51
mi
from
Houston, TX
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 51
mi
from
Houston, TX
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 027
mi
from
Houston, TX
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 027
mi
from
Houston, TX
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 014
mi
from
Clinton, UT
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 014
mi
from
Clinton, UT
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 029
mi
from
Salt Lake City, UT
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 029
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 064
mi
from
Charlottesville, VA
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 064
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative site 031
mi
from
Norfolk, VA
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative site 031
mi
from
Norfolk, VA
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 124
mi
from
Roanoke, VA
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 124
mi
from
Roanoke, VA
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 014
mi
from
Bothell, WA
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 014
mi
from
Bothell, WA
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 121
mi
from
Seattle, WA
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 121
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 119
mi
from
Charleston, WV
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 119
mi
from
Charleston, WV
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 007
mi
from
Middleton, WI
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 007
mi
from
Middleton, WI
Click here to add this to my saved trials
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated:  8/30/2012
Forest Investigative Site 138
mi
from
Milwaukee, WI
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status: Enrolling
Updated: 8/30/2012
Forest Investigative Site 138
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Reserach Site
mi
from
Escondido, CA
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Reserach Site
mi
from
Escondido, CA
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
San Diego, CA
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Atlanta, GA
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Evanston, IL
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Kansas City, KA
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Detroit, MI
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Teaneck, NJ
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Teaneck, NJ
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Bronx, NY
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Asheville, NC
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Akron, OH
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Status: Enrolling
Updated:  10/24/2012
Clinvest
mi
from
Springfield, MO
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Status: Enrolling
Updated: 10/24/2012
Clinvest
mi
from
Springfield, MO
Click here to add this to my saved trials
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Status: Enrolling
Updated:  10/24/2012
Nashville Neuroscience Group, PC
mi
from
Nashville, TN
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Status: Enrolling
Updated: 10/24/2012
Nashville Neuroscience Group, PC
mi
from
Nashville, TN
Click here to add this to my saved trials
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Status: Enrolling
Updated:  10/24/2012
Scott and White Memorial Hospital & Clinic
mi
from
Temple, TX
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Status: Enrolling
Updated: 10/24/2012
Scott and White Memorial Hospital & Clinic
mi
from
Temple, TX
Click here to add this to my saved trials
Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients
24-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Exelon® [Rivastigmine] Transdermal Patch in 120 APOE e4 Positive Amnestic MCI Patients
Status: Enrolling
Updated:  12/13/2012
Cleveland Clinic
mi
from
Cleveland, OH
Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients
24-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Exelon® [Rivastigmine] Transdermal Patch in 120 APOE e4 Positive Amnestic MCI Patients
Status: Enrolling
Updated: 12/13/2012
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
Premiere Research Institute
mi
from
West Palm Beach, FL
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
Premiere Research Institute
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
University of Kentucky
mi
from
Lexington, KY
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
Norton Healthcare
mi
from
Louisville, KY
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
Norton Healthcare
mi
from
Louisville, KY
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
Boston Center for Memory
mi
from
Brookline, MA
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
Boston Center for Memory
mi
from
Brookline, MA
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
Duke University
mi
from
Durham, NC
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
Univ of Pennsylvania
mi
from
Philadelphia, PA
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
The Memory Clinic
mi
from
Bennington, VT
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
The Memory Clinic
mi
from
Bennington, VT
Click here to add this to my saved trials
Cognitive Dysfunction in Postural Tachycardia Syndrome
Origins of Cognitive Dysfunction in Postural Tachycardia Syndrome (POTS)
Status: Enrolling
Updated:  1/7/2013
Vanderbilt University
mi
from
Nashville, TN
Cognitive Dysfunction in Postural Tachycardia Syndrome
Origins of Cognitive Dysfunction in Postural Tachycardia Syndrome (POTS)
Status: Enrolling
Updated: 1/7/2013
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder
Cognitive Rehabilitation of OIF/OEF Veterans With Cognitive Disorder
Status: Enrolling
Updated:  1/15/2013
VA San Diego Healthcare System, San Diego
mi
from
San Diego, CA
Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder
Cognitive Rehabilitation of OIF/OEF Veterans With Cognitive Disorder
Status: Enrolling
Updated: 1/15/2013
VA San Diego Healthcare System, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder
Cognitive Rehabilitation of OIF/OEF Veterans With Cognitive Disorder
Status: Enrolling
Updated:  1/15/2013
VA Medical Center, Boise
mi
from
Boise, ID
Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder
Cognitive Rehabilitation of OIF/OEF Veterans With Cognitive Disorder
Status: Enrolling
Updated: 1/15/2013
VA Medical Center, Boise
mi
from
Boise, ID
Click here to add this to my saved trials
Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder
Cognitive Rehabilitation of OIF/OEF Veterans With Cognitive Disorder
Status: Enrolling
Updated:  1/15/2013
VA Medical Center, Portland
mi
from
Portland, OR
Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder
Cognitive Rehabilitation of OIF/OEF Veterans With Cognitive Disorder
Status: Enrolling
Updated: 1/15/2013
VA Medical Center, Portland
mi
from
Portland, OR
Click here to add this to my saved trials
Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder
Cognitive Rehabilitation of OIF/OEF Veterans With Cognitive Disorder
Status: Enrolling
Updated:  1/15/2013
VA Puget Sound Health Care System, Seattle
mi
from
Seattle, WA
Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder
Cognitive Rehabilitation of OIF/OEF Veterans With Cognitive Disorder
Status: Enrolling
Updated: 1/15/2013
VA Puget Sound Health Care System, Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Mechanisms of Insulin Facilitation of Memory
Mechanisms of Insulin Facilitation of Memory
Status: Enrolling
Updated:  1/15/2013
University of Texas at Austin
mi
from
Austin, TX
Mechanisms of Insulin Facilitation of Memory
Mechanisms of Insulin Facilitation of Memory
Status: Enrolling
Updated: 1/15/2013
University of Texas at Austin
mi
from
Austin, TX
Click here to add this to my saved trials
Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis
Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis
Status: Enrolling
Updated:  1/15/2013
UCalifornia at Los Angeles
mi
from
Los Angeles, CA
Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis
Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis
Status: Enrolling
Updated: 1/15/2013
UCalifornia at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis
Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis
Status: Enrolling
Updated:  1/15/2013
CAl State University at Northridge
mi
from
Northridge, CA
Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis
Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis
Status: Enrolling
Updated: 1/15/2013
CAl State University at Northridge
mi
from
Northridge, CA
Click here to add this to my saved trials
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  1/17/2013
Clinical Research Facility
mi
from
Phoenix, AZ
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 1/17/2013
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  1/17/2013
Clinical Research Facility
mi
from
Fort Smith, AR
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 1/17/2013
Clinical Research Facility
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  1/17/2013
Clinical Research Facility
mi
from
Santa Clara, CA
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 1/17/2013
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials